Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs

{
  "publication_number": "US6410707B2",
  "country": "US",
  "kind": "B2",
  "title": "Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs",
  "abstract": "A process for the recombinant preparation of a calcitonin fragment and the use of the fragment in the preparation of calcitonin and related analogs is provided. The process includes recombinantly forming a fusion protein which includes the calcitonin fragment linked to a carbonic anhydrase. The recombinantly formed fusion protein is subsequently cleaved to produce a polypeptide which includes the calcitonin fragment. A method for producing a calcitonin carba analog which includes condensing a desaminononapeptide with the recombinantly formed calcitonin fragment is also provided.",
  "claims": [
    "1. An isolated nucleic acid comprising a polynucleotide having the sequence of SEQ ID NO: 11.",
    "2. A recombinant DNA construct comprising a polynucleotide having the sequence of SEQ ID NO: 11."
  ],
  "description_excerpt": "This application is a Divisional of application Ser. No. 09/139,819 filed Aug. 25, 1998, now U.S. Pat. No. 6,251,635 which is a Divisional of application Ser. No. 08/595,868 filed Feb. 6, 1996, now U.S. Pat. No. 5,962,270.\n\nCalcitonins and related analogs, such as Elcatonin, are known polypeptides which can be employed for treating bone atrophy (see, e.g., U.S. Pat. No. 4,086,221). Naturally occurring calcitonins, such as eel, salmon or human calcitonin, are C-terminal amidated polypeptides which consist of 32 amino acids, the first and the seventh amino acids in each case being L-cysteines whose mercapto groups are connected to each other by the formation of a disulfide bridge. The natural calcitonins can be obtained, for example, by extraction from the mammalian thyroid gland (see, e.g., U.S. Pat. No. 5,428,129).\n\nElcatonin is a modified synthetic “carba” analog of calcitonin whose activity is comparable with that of eel calcitonin (Morikawa et al., Experienta, 32, 1004, (1976)). In contrast to eel calcitonin, Elcatonin lacks an amino terminal end and the disulfide bridge of eel calcitonin has been replaced by a - (CH 2) 5 - “carbon bridge.”\n\nCurrently, a variety of processes are known for the preparation of Elcatonin using purely chemical methods. These chemical methods involve condensation of the corresponding amino acids or peptides (see, e.g., U.S. Pat. Nos. 4,086,221 and 5,428,129). The purely chemical methods, however, all suffer from the disadvantage that, due to the elaborate purification methods required, the Elcatonin is obtained in low yield and its preparation is consequently very expensive.",
  "cpc": [
    "C07K 14/585",
    "C07K 2319/00",
    "C12N 9/88"
  ],
  "ipc": [
    "C07K 14/585",
    "C12N 15/16",
    "C12N 9/88"
  ],
  "assignees": [
    "BioNebraska Inc"
  ],
  "inventors": [
    "Fred W. Wagner",
    "Jay S. Stout",
    "Dennis B. Henriksen",
    "Bruce E. Partridge",
    "Bart Holmquist",
    "Julie A. Frank"
  ],
  "filing_date": "2001-01-02",
  "publication_date": "2002-06-25",
  "grant_date": "2002-06-25",
  "priority_date": "1996-02-06",
  "application_number": "US-75091301-A",
  "family_id": "24385018",
  "cited_by_count": 50,
  "citations": [
    "US3798203A",
    "US3891614A",
    "US4086221A",
    "GB1590645A",
    "US5332664A",
    "US4401593A",
    "WO1983004028A1",
    "US5093241A",
    "EP0191869A1",
    "US4659804A",
    "US4804742A",
    "US4743677A",
    "US4644054A",
    "US5143844A",
    "US4658014A",
    "CA1273750A",
    "US5013653A",
    "WO1989010934A1",
    "JPH02219589A",
    "WO1990007005A1",
    "US5428129A",
    "US5196316A",
    "JPH0459795A",
    "US5595887A",
    "JPH05255391A",
    "US5440012A",
    "JPH05140199A",
    "JPH05247087A",
    "US5656456A",
    "JPH06157593A",
    "US5527881A",
    "WO1994015962A2",
    "EP0618219A1",
    "JPH06298798A",
    "WO1995018152A1"
  ]
}